Evaluating ibrutinib in the treatment of symptomatic Waldenstrom’s macroglobulinemia

References

• Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol. 2003;30(2):110–115. doi:10.1053/sonc.2003.5008212720118
   PubMed Web of Science ®Google Scholar
• Leblond V, Kastritis E, Advani R, et al. Treatment recommendations from the Eighth International Workshop on Waldenstrom’s Macroglobulinemia. Blood. 2016;128(10):1321–1328. doi:10.1182/blood-2016-04-71123427432877
   PubMed Web of Science ®Google Scholar
• Buske C, Seymour JF. Immunochemotherapy in Waldenstrom macroglobulinemia - still the backbone of treatment. Leuk Lymphoma. 2015;56(9):2489–2490. doi:10.3109/10428194.2015.105893826054374
   PubMed Web of Science ®Google Scholar
• Gavriatopoulou M, Ntanasis-Stathopoulos I, Kastritis E, Dimopoulos MA. How I treat rituximab refractory patients with WM. Oncotarget. 2018;9(96):36824–36825. doi:10.18632/oncotarget.2641130627320
   PubMedGoogle Scholar
• Castillo JJ, Kanan S, Meid K, Manning R, Hunter ZR, Treon SP. Rituximab intolerance in patients with Waldenstrom macroglobulinaemia. Br J Haematol. 2016;174(4):645–648. doi:10.1111/bjh.1379426523929
   PubMed Web of Science ®Google Scholar
• FDA expands approved use of Imbruvica for rare form of non-Hodgkin lymphoma: first drug approved to treat Waldenström’s macroglobulinemia. [press release]. 2015.
   Google Scholar
• Charalambous A, Schwarzbich MA, Witzens-Harig M. Ibrutinib. Recent results in cancer research. 2018;212:133–168. doi:10.1007/978-3-319-91439-8_730069629
   PubMedGoogle Scholar
• Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463(7277):88–92. doi:10.1038/nature0863820054396
   PubMed Web of Science ®Google Scholar
• Stevenson FK, Krysov S, Davies AJ, Steele AJ, Packham G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2011;118(16):4313–4320. doi:10.1182/blood-2011-06-33885521816833
   PubMed Web of Science ®Google Scholar
• Sideras P, Muller S, Shiels H, et al. Genomic organization of mouse and human Bruton’s agammaglobulinemia tyrosine kinase (Btk) loci. J Immunol. 1994;153(12):5607–5617.7989760
   PubMed Web of Science ®Google Scholar
• Seda V, Mraz M. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells. Eur J Haematol. 2015;94(3):193–205. doi:10.1111/ejh.1242725080849
   PubMed Web of Science ®Google Scholar
• Satterthwaite AB, Witte ON. The role of Bruton’s tyrosine kinase in B-cell development and function: a genetic perspective. Immunol Rev. 2000;175:120–127.10933597
   PubMed Web of Science ®Google Scholar
• Imbruvica (ibrutinib) Capsules [prescribing Information]. Sunnyvale, CA: Pharmacyclics, Inc; 3 2016.
   Google Scholar
• Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenstrom’s macroglobulinemia. N Engl J Med. 2012;367(9):826–833. doi:10.1056/NEJMoa120071022931316
   PubMed Web of Science ®Google Scholar
• Watters TM, Kenny EF, O’Neill LA. Structure, function and regulation of the Toll/IL-1 receptor adaptor proteins. Immunol Cell Biol. 2007;85(6):411–419. doi:10.1038/sj.icb.710009517667936
   PubMed Web of Science ®Google Scholar
• Lin SC, Lo YC, Wu H. Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. Nature. 2010;465(7300):885–890. doi:10.1038/nature0912120485341
   PubMed Web of Science ®Google Scholar
• Leleu X, Eeckhoute J, Jia X, et al. Targeting NF-kappaB in Waldenstrom macroglobulinemia. Blood. 2008;111(10):5068–5077. doi:10.1182/blood-2007-09-11517018334673
   PubMed Web of Science ®Google Scholar
• Shinners NP, Carlesso G, Castro I, et al. Bruton’s tyrosine kinase mediates NF-kappa B activation and B cell survival by B cell-activating factor receptor of the TNF-R family. J Immunol. 2007;179(6):3872–3880. doi:10.4049/jimmunol.179.6.387217785824
   PubMed Web of Science ®Google Scholar
• Yang G, Zhou Y, Liu X, et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia. Blood. 2013;122(7):1222–1232. doi:10.1182/blood-2012-12-47511123836557
   PubMed Web of Science ®Google Scholar
• Chen JG, Liu X, Munshi M, et al. BTK(Cys481Ser) drives ibrutinib resistance via ERK1/2 and protects BTK(wild-type) MYD88-mutated cells by a paracrine mechanism. Blood. 2018;131(18):2047–2059. doi:10.1182/blood-2017-10-81175229496671
   PubMed Web of Science ®Google Scholar
• Yang G, Buhrlage SJ, Tan L, et al. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. Blood. 2016;127(25):3237–3252. doi:10.1182/blood-2016-01-69509827143257
   PubMed Web of Science ®Google Scholar
• Hunter ZR, Xu L, Yang G, et al. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood. 2014;123(11):1637–1646. doi:10.1182/blood-2013-09-52580824366360
   PubMed Web of Science ®Google Scholar
• Busillo JM, Armando S, Sengupta R, Meucci O, Bouvier M, Benovic JL. Site-specific phosphorylation of CXCR4 is dynamically regulated by multiple kinases and results in differential modulation of CXCR4 signaling. J Biol Chem. 2010;285(10):7805–7817. doi:10.1074/jbc.M109.09117320048153
   PubMed Web of Science ®Google Scholar
• Dotta L, Tassone L, Badolato R. Clinical and genetic features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) syndrome. Curr Mol Med. 2011;11(4):317–325.21506920
   PubMed Web of Science ®Google Scholar
• Roccaro AM, Sacco A, Jimenez C, et al. C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. Blood. 2014;123(26):4120–4131. doi:10.1182/blood-2014-03-56458324711662
   PubMed Web of Science ®Google Scholar
• Xu L, Hunter ZR, Tsakmaklis N, et al. Clonal architecture of CXCR4 WHIM-like mutations in Waldenstrom Macroglobulinaemia. Br J Haematol. 2016;172(5):735–744. doi:10.1111/bjh.1389726659815
   PubMed Web of Science ®Google Scholar
• Treon SP, Cao Y, Xu L, Yang G, Liu X, Hunter ZR. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood. 2014;123(18):2791–2796. doi:10.1182/blood-2014-01-55090524553177
   PubMed Web of Science ®Google Scholar
• Busillo JM, Benovic JL. Regulation of CXCR4 signaling. Biochim Biophys Acta. 2007;1768(4):952–963. doi:10.1016/j.bbamem.2006.11.00217169327
   PubMed Web of Science ®Google Scholar
• Cao Y, Hunter ZR, Liu X, et al. CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstrom macroglobulinaemia cells. Br J Haematol. 2015;168(5):701–707. doi:10.1111/bjh.1320025371371
   PubMed Web of Science ®Google Scholar
• Cao Y, Hunter ZR, Liu X, et al. The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s Macroglobulinemia. Leukemia. 2015;29(1):169–176. doi:10.1038/leu.2014.18724912431
   PubMed Web of Science ®Google Scholar
• Martin P, Maddocks K, Leonard JP, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127(12):1559–1563. doi:10.1182/blood-2015-10-67314526764355
   PubMed Web of Science ®Google Scholar
• Xu L, Tsakmaklis N, Yang G, et al. Acquired mutations associated with ibrutinib resistance in Waldenstrom macroglobulinemia. Blood. 2017;129(18):2519–2525. doi:10.1182/blood-2017-01-76172628235842
   PubMed Web of Science ®Google Scholar
• Paulus A, Akhtar S, Yousaf H, et al. Waldenstrom macroglobulinemia cells devoid of BTK(C481S) or CXCR4(WHIM-like) mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. Blood Cancer J. 2017;7(5):e565. doi:10.1038/bcj.2017.4028548645
   PubMed Web of Science ®Google Scholar
• Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31(1):88–94. doi:10.1200/JCO.2012.42.790623045577
   PubMed Web of Science ®Google Scholar
• Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenstrom’s macroglobulinemia. N Engl J Med. 2015;372(15):1430–1440. doi:10.1056/NEJMoa150154825853747
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Trotman J, Tedeschi A, et al. Ibrutinib for patients with rituximab-refractory Waldenstrom’s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017;18(2):241–250. doi:10.1016/S1470-2045(16)30632-527956157
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Tedeschi A, Trotman J, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenstrom’s macroglobulinemia. N Engl J Med. 2018;378(25):2399–2410. doi:10.1056/NEJMoa180291729856685
   PubMed Web of Science ®Google Scholar
• Karlin L, Besson H, Tapprich C, Garside J, Salles G. Efficacy of Ibrutinib-Rituximab versus Real-World (RW) treatments for patients with Waldenström’s Macroglobulinemia (WM): adjusted comparison of iNNOVATE and the Lyon-Sud RW database. Blood. 2018;132(Suppl 1):1604. doi:10.1182/blood-2018-04-84802830108064
   PubMed Web of Science ®Google Scholar
• Treon SP, Gustine J, Meid K, et al. Ibrutinib monotherapy in symptomatic, treatment-naive patients with Waldenstrom macroglobulinemia. J Clin Oncol. 2018;36(27):2755–2761. doi:10.1200/JCO.2018.78.642630044692
   PubMed Web of Science ®Google Scholar
• Buske C, Tedeschi A, Trotman J, et al. Ibrutinib treatment in Waldenström’s Macroglobulinemia: follow-up efficacy and safety from the iNNOVATETM study. Blood. 2018;132(Suppl 1):149.
   Web of Science ®Google Scholar
• de Zwart L, Snoeys J, De Jong J, Sukbuntherng J, Mannaert E, Monshouwer M. Ibrutinib dosing strategies based on interaction potential of CYP3A4 perpetrators using physiologically based pharmacokinetic modeling. Clin Pharmacol Ther. 2016;100(5):548–557. doi:10.1002/cpt.41927367453
   PubMed Web of Science ®Google Scholar
• de Weerdt I, Koopmans SM, Kater AP, van Gelder M. Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach. Haematologica. 2017;102(10):1629–1639. doi:10.3324/haematol.2017.16410328775119
   PubMed Web of Science ®Google Scholar
• Yun S, Vincelette ND, Acharya U, Abraham I. Risk of atrial fibrillation and bleeding diathesis associated with ibrutinib treatment: a systematic review and pooled analysis of four randomized controlled trials. Clin Lymphoma Myeloma Leuk. 2017;17(1):31–37 e13. doi:10.1016/j.clml.2016.09.01027780690
   PubMed Web of Science ®Google Scholar
• Bye AP, Unsworth AJ, Vaiyapuri S, Stainer AR, Fry MJ, Gibbins JM. Ibrutinib inhibits platelet integrin alphaiibbeta3 outside-in signaling and thrombus stability but not adhesion to collagen. Arterioscler Thromb Vasc Biol. 2015;35(11):2326–2335. doi:10.1161/ATVBAHA.115.30613026359510
   PubMed Web of Science ®Google Scholar
• Thorp BC, Badoux X. Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management. Leuk Lymphoma. 2018;59(2):311–320. doi:10.1080/10428194.2017.133987428629235
   PubMed Web of Science ®Google Scholar
• McMullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ, Tam CS. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014;124(25):3829–3830. doi:10.1182/blood-2014-10-60427225498454
   PubMed Web of Science ®Google Scholar
• Gustine JN, Meid K, Dubeau TE, Treon SP, Castillo JJ. Atrial fibrillation associated with ibrutinib in Waldenstrom macroglobulinemia. Am J Hematol. 2016;91(6):E312–E313. doi:10.1002/ajh.2436626994323
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Gustine JN, Meid K, Dubeau T, Severns P, Treon SP. Ibrutinib withdrawal symptoms in patients with Waldenstrom macroglobulinemia. Haematologica. 2018;103(7):e307–e310. doi:10.3324/haematol.2017.18690829472352
   PubMed Web of Science ®Google Scholar
• Niemann CU, Herman SE, Maric I, et al. Disruption of in vivo chronic lymphocytic leukemia tumor-microenvironment interactions by ibrutinib–findings from an investigator-initiated Phase II study. Clin Cancer Res. 2016;22(7):1572–1582. doi:10.1158/1078-0432.CCR-15-196526660519
   PubMed Web of Science ®Google Scholar
• Ping L, Ding N, Shi Y, et al. The Bruton’s tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages. Oncotarget. 2017;8(24):39218–39229. doi:10.18632/oncotarget.1683628424405
   PubMedGoogle Scholar
• Ren L, Campbell A, Fang H, et al. Analysis of the effects of the Bruton’s tyrosine kinase (Btk) inhibitor ibrutinib on monocyte Fcgamma Receptor (FcgammaR) function. J Biol Chem. 2016;291(6):3043–3052. doi:10.1074/jbc.M115.68725126627823
   PubMed Web of Science ®Google Scholar
• Gustine JN, Meid K, Dubeau T, et al. Ibrutinib discontinuation in Waldenstrom macroglobulinemia: etiologies, outcomes, and IgM rebound. Am J Hematol. 2018;93(4):511–517. doi:10.1002/ajh.2502329280186
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Gustine JN, Meid K, et al. Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenstrom macroglobulinemia. Haematologica. 2018;103(10):e466–e468. doi:10.3324/haematol.2018.19199929773590
   PubMed Web of Science ®Google Scholar
• Tam CS, LeBlond V, Novotny W, et al. A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenstrom macroglobulinemia. Future Oncol. 2018;14(22):2229–2237. doi:10.2217/fon-2018-016329869556
   PubMed Web of Science ®Google Scholar
• Trotman J, Opat S, Marlton P, et al. Bruton’s Tyrosine Kinase (BTK) inhibitor BGB-3111 demonstrates high very good partial response (VGPR) rate in patients with Waldenström macroglobulinemia (WM). Hematol Oncol. 2017;35(S2):70–71. doi:10.1002/hon.240428591420
   PubMed Web of Science ®Google Scholar
• Harrington BK, Gulrajani M, Covey T, et al. ACP-196 is a second generation inhibitor of bruton tyrosine Kinase (BTK) with enhanced target specificity. Blood. 2015;126(23):2908.
   Web of Science ®Google Scholar
• Byrd JC, Harrington B, O’Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):323–332. doi:10.1056/NEJMoa150998126641137
   PubMed Web of Science ®Google Scholar
• Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391(10121):659–667. doi:10.1016/S0140-6736(17)33108-229241979
   PubMed Web of Science ®Google Scholar
• Owen R, McCarthy H, Rule S, et al. Acalabrutinib in Patients (pts) with Waldenström Macroglobulinemia (WM) ASCO 2018 Abstract 7501.
   Google Scholar
• Neuman LL, Ward R, Arnold D, et al. First-in-human Phase 1a study of the safety, pharmacokinetics, and pharmacodynamics of the noncovalent Bruton Tyrosine Kinase (BTK) inhibitor SNS-062 in healthy subjects. Blood. 2016;128(22):2032.
   Web of Science ®Google Scholar